Psittacosis (Chlamydia psittaci / Avian Chlamydiosis)

Psittacosis, also known as avian chlamydiosis or parrot fever, is a systemic, zoonotic infectious disease of birds caused by the obligate intracellular bacterium Chlamydia psittaci. The disease primarily affects psittacine birds (parrots, macaws, cockatiels, budgerigars) but can also infect other avian species including pigeons, doves, turkeys, ducks, and occasionally humans. The bacterium has a unique biphasic life cycle, existing as an environmentally resistant elementary body (EB) outside the host and a metabolically active reticulate body (RB) inside host cells. In birds, the infection can range from subclinical to acute fatal disease, with clinical signs including respiratory distress, conjunctivitis, diarrhea, and lethargy. The disease is of significant public health concern due to its zoonotic potential, causing flu-like symptoms in humans and potentially severe pneumonia. In avian medicine, psittacosis is a reportable disease in many countries, and its diagnosis requires a combination of clinical suspicion, serology, PCR, and isolation. Treatment typically involves doxycycline, which is the drug of choice, administered for a prolonged period to eliminate the infection. Prevention relies on strict biosecurity, quarantine of new birds, and regular screening of breeding flocks.

The primary causative agent is Chlamydia psittaci, a Gram-negative, obligate intracellular bacterium belonging to the family Chlamydiaceae. The organism exists in two forms: the elementary body (EB), which is metabolically inert, environmentally resistant, and infectious, and the reticulate body (RB), which is the intracellular replicative form. The EB attaches to host cell membranes, is internalized via endocytosis, and differentiates into RBs within a membrane-bound inclusion. RBs divide by binary fission and eventually differentiate back into EBs, which are released by cell lysis or extrusion, perpetuating the infection. C. psittaci has multiple serovars (A-F) and genotypes, with serovar A commonly associated with psittacine birds, serovar B with pigeons, and serovar D with turkeys. The bacterium is susceptible to heat (inactivated at 56°C for 5 minutes) and common disinfectants, but EBs can survive for months in dried feces and dust. Transmission occurs primarily via inhalation of aerosolized fecal dust or respiratory secretions, but also through direct contact with infected birds or fomites. In birds, the organism initially infects the respiratory epithelium and macrophages, then disseminates hematogenously to the liver, spleen, and other organs, leading to systemic disease.

Psittacosis is distributed worldwide, with higher prevalence in tropical and subtropical regions where psittacine birds are common pets. In captive bird populations, the prevalence of C. psittaci infection varies widely, with studies reporting 5-30% in pet birds, but higher in recently imported or stressed birds. Species susceptibility varies: budgerigars (Melopsittacus undulatus) and cockatiels (Nymphicus hollandicus) are highly susceptible and often show acute disease, while Amazon parrots (Amazona spp.) and macaws (Ara spp.) may be more resistant and serve as chronic carriers. Pigeons (Columba livia) and doves are common reservoirs, often showing subclinical infection. Turkeys and ducks can be infected, leading to economic losses in poultry. Age predisposition: young birds are more susceptible to clinical disease, while adults may be asymptomatic carriers. Sex predilection is not significant. Husbandry factors such as overcrowding, poor ventilation, inadequate nutrition, and stress (e.g., shipping, breeding) increase the risk of clinical outbreaks. Wild birds, especially psittacines, are natural reservoirs, and the illegal pet trade contributes to the spread. In humans, psittacosis is an occupational hazard for pet shop workers, veterinarians, and poultry processors, with an estimated incidence of 1-2% of community-acquired pneumonia cases.

The pathophysiology of psittacosis begins with inhalation of infectious elementary bodies (EBs) into the respiratory tract. EBs attach to and enter epithelial cells and macrophages in the respiratory mucosa, where they differentiate into reticulate bodies (RBs) and replicate within a membrane-bound inclusion. The infection triggers a strong innate immune response, with release of pro-inflammatory cytokines (IL-1, IL-6, TNF-alpha) and recruitment of neutrophils and macrophages. This leads to inflammation of the respiratory tract, conjunctiva, and air sacs, causing rhinitis, sinusitis, conjunctivitis, and airsacculitis. The organism then disseminates via the bloodstream to the liver, spleen, and other organs, where it causes focal necrosis and inflammation. In the liver, this results in hepatomegaly and elevated liver enzymes. The spleen may become enlarged and congested. The systemic inflammatory response can lead to fever, lethargy, and anorexia. In severe cases, the infection can cause vasculitis, leading to thrombosis and infarction. Chronic infection may result in persistent shedding of EBs in feces and respiratory secretions, maintaining the carrier state. In birds, the disease can be exacerbated by concurrent infections (e.g., circovirus, polyomavirus) or immunosuppression. The immune response involves both humoral (IgM, IgG) and cell-mediated immunity, but the bacterium can evade clearance by modulating host cell apoptosis and antigen presentation.

Intrinsic factors: Species-specific susceptibility (budgerigars, cockatiels are highly susceptible; Amazon parrots may be carriers). Age: Young birds are more prone to clinical disease due to immature immune systems. Sex: No significant sex predilection. Genetic factors: Some avian species have innate resistance. Extrinsic factors: Husbandry stressors such as overcrowding, poor ventilation, high ammonia levels, temperature fluctuations, and inadequate nutrition (e.g., vitamin A deficiency) compromise mucosal immunity. Poor sanitation facilitates fecal-oral transmission. Introduction of new birds without quarantine is a major risk factor. Stress from shipping, breeding, or molting can reactivate latent infections. In humans, immunosuppression, pregnancy, and occupational exposure increase risk. Environmental factors: High humidity and warm temperatures favor EB survival in the environment. Wild bird contact, especially pigeons, can introduce infection to captive flocks.

Clinical signs in birds vary from subclinical to severe and can be acute, chronic, or intermittent. Acute disease: Sudden death, especially in budgerigars and cockatiels. Affected birds show lethargy, anorexia, ruffled feathers, and weight loss. Respiratory signs include dyspnea, tail bobbing, nasal discharge, and conjunctivitis with ocular discharge. Gastrointestinal signs: Greenish-yellow or watery diarrhea, sometimes with urates. Chronic disease: More common in larger parrots; signs include gradual weight loss, intermittent anorexia, lethargy, and respiratory signs. Conjunctivitis and sinusitis may be present. Some birds develop hepatomegaly, leading to abdominal distension. Neurological signs (tremors, seizures) are rare but can occur. In pigeons, signs may be mild, with only conjunctivitis and diarrhea. In turkeys, respiratory distress and decreased egg production are noted. In humans, symptoms include fever, chills, headache, myalgia, and a dry cough, progressing to atypical pneumonia. Physical examination findings in birds: Poor body condition, dehydration, abnormal respiratory sounds (wheezing, crackles), conjunctival hyperemia, and hepatomegaly on palpation. In severe cases, birds may be unable to perch and may sit on the floor of the cage.

1. Avian influenza (H5N1, H7N9): Acute respiratory distress, high mortality, but also neurological signs; PCR and virus isolation differentiate. 2. Newcastle disease: Respiratory and neurological signs, but also gastrointestinal; PCR and serology. 3. Avian mycoplasmosis (Mycoplasma gallisepticum): Chronic respiratory disease, sinusitis, but no hepatomegaly; PCR and culture. 4. Aspergillosis: Respiratory signs, but typically granulomatous lesions in air sacs; radiography and endoscopy with fungal culture. 5. Bacterial septicemia (E. coli, Pasteurella): Non-specific signs, but blood cultures and necropsy findings. 6. Chlamydia-related conjunctivitis (other Chlamydia spp.): Similar signs, but PCR can identify species. 7. Psittacine beak and feather disease (PBFD): Feather loss and beak deformities, but also immunosuppression; PCR for circovirus. 8. Polyomavirus infection: Acute death in young birds, but also feather abnormalities; PCR. 9. Hepatic lipidosis: Hepatomegaly, but history of high-fat diet; biochemistry and biopsy. 10. Toxoplasmosis: Neurological signs, but also systemic; serology and PCR.

1. Clinical triage: Isolate the bird, use appropriate personal protective equipment (PPE) due to zoonotic risk. 2. Physical examination: Assess body condition, hydration, respiratory effort, and conjunctival health. 3. Sample collection: Collect choanal and cloacal swabs for PCR (preferred) or culture. Also collect blood for serology (e.g., ELISA, IFA) and hematology/biochemistry. 4. PCR: Real-time PCR on swabs is highly sensitive and specific; positive result confirms infection. 5. Serology: Acute and convalescent titers (2-4 weeks apart) can support diagnosis; IgM indicates recent infection, IgG indicates past exposure. 6. Hematology: Look for leukocytosis with heterophilia and monocytosis. 7. Biochemistry: Elevated AST, bile acids, and globulins suggest liver involvement. 8. Radiography: Thoracic and abdominal radiographs may show hepatomegaly, air sac thickening, or pneumonia. 9. Endoscopy: If available, visualize air sacs and liver; collect biopsies for histopathology and PCR. 10. Treatment trial: If PCR is not available, a positive response to doxycycline therapy can support diagnosis. 11. Confirmatory testing: Culture of C. psittaci is definitive but requires specialized laboratories and is hazardous.

Hematology: Complete blood count often reveals leukocytosis (20,000-50,000 cells/µL) with heterophilia and monocytosis. Lymphopenia may be present in acute cases. PCV may be normal or decreased in chronic cases. Serum biochemistry: Elevated AST (aspartate aminotransferase) and bile acids indicate hepatic involvement. Globulins may be elevated due to chronic inflammation. Creatine kinase (CK) may be elevated if there is muscle damage. Uric acid may be elevated in renal impairment. Fecal analysis: Direct smear and staining may reveal inflammatory cells, but not specific. PCR on fecal or cloacal swabs is more sensitive. Serology: ELISA and IFA can detect antibodies; a four-fold rise in titer between acute and convalescent samples is diagnostic. Urinalysis: Not commonly performed in birds, but may show urates and protein. PCR: Real-time PCR on choanal/cloacal swabs or blood is the most sensitive and specific test. Culture: Isolation of C. psittaci from swabs or tissues is definitive but requires biosafety level 3 facilities.

Radiography: Whole-body radiographs (lateral and ventrodorsal views) may reveal hepatomegaly (enlarged liver silhouette), splenomegaly, air sac thickening, and pulmonary infiltrates. In chronic cases, there may be evidence of pneumonia or airsacculitis. Ultrasonography: Coelomic ultrasound can assess liver size and echotexture, and detect ascites. Echocardiography is not typically indicated. CT: Computed tomography provides detailed images of the respiratory tract and coelomic organs, useful for detecting granulomas or abscesses. MRI: Not commonly used but can evaluate soft tissue structures. Endoscopy: Rigid endoscopy allows direct visualization of the air sacs, liver, and spleen; biopsy samples can be collected for histopathology and PCR. Endoscopic findings may include air sac thickening, caseous exudate, and hepatomegaly with discoloration.

Cytology: Impression smears of conjunctival or choanal swabs may show intracytoplasmic inclusions (elementary bodies) in epithelial cells, but this is insensitive. Fine-needle aspiration of the liver or spleen may reveal inflammatory cells and possibly inclusions. Histopathology: On necropsy, the liver shows multifocal necrosis and inflammation with infiltration of heterophils and macrophages. Intracytoplasmic basophilic inclusions (elementary bodies) may be seen in hepatocytes and Kupffer cells. The spleen shows lymphoid depletion and necrosis. The lungs and air sacs show fibrinous exudate and inflammatory infiltrates. Immunohistochemistry (IHC) using monoclonal antibodies can confirm the presence of C. psittaci antigens in tissues. PCR on formalin-fixed tissues is also possible.

Treatment of psittacosis involves antimicrobial therapy, supportive care, and environmental management. The drug of choice is doxycycline, which is bacteriostatic but effective. Doxycycline can be administered orally (PO) at 25-50 mg/kg q12h for 45 days, or as an injectable formulation (Vibramycin) at 50-100 mg/kg IM q7d for 4-6 weeks. Alternatively, doxycycline medicated feed (0.1% doxycycline in seed or pellets) can be used for 45 days. Enrofloxacin (10-15 mg/kg PO q12h) is less effective but can be used as an alternative, though it may not eliminate the infection. Azithromycin (40 mg/kg PO q24h) has been used with some success. Supportive care: Fluid therapy (lactated Ringer's solution or 0.9% saline) at 50-100 mL/kg/day SC or IV, depending on hydration status. Nutritional support: Syringe feeding with a critical care formula (e.g., Oxbow Critical Care) at 1-2% body weight per feeding, 2-4 times daily. Provide a warm, quiet environment (85-90°F for small birds). Vitamin A supplementation may be beneficial. In severe respiratory distress, oxygen therapy may be needed. Isolation of affected birds is essential to prevent spread. Treatment should continue for at least 45 days to ensure elimination of the organism. In humans, doxycycline 100 mg PO q12h for 7-10 days is the standard treatment.

The prognosis for psittacosis in birds is generally good if treatment is initiated early and continued for the full duration. Acute cases in highly susceptible species (budgerigars) may have a guarded prognosis due to rapid progression. Chronic carriers may respond well but require prolonged therapy. Negative prognostic indicators include severe respiratory distress, marked leukocytosis, elevated liver enzymes, and concurrent infections. With appropriate treatment, most birds recover within 2-4 weeks, but shedding may persist for months. In humans, the prognosis is excellent with prompt antibiotic therapy, but untreated cases can be fatal. Long-term sequelae in birds are rare, but chronic liver damage may occur. Reinfection is possible, so biosecurity measures are important.

Follow-up is crucial to ensure complete recovery and prevent zoonotic transmission. Re-check the bird at 2-week intervals during treatment. Monitor weight, appetite, and clinical signs. Repeat PCR on choanal/cloacal swabs at 2 weeks after completion of therapy to confirm clearance; a negative PCR is ideal. Serology can be repeated to assess antibody titers, but antibodies may persist for months. Perform a complete blood count and biochemistry panel at the end of treatment to assess organ function. For breeding flocks, screen all birds for C. psittaci before introduction. Long-term husbandry audit: Ensure proper ventilation, reduce stress, and maintain good hygiene. Quarantine new birds for at least 30-60 days. In humans, follow-up with a physician is recommended to ensure resolution of pneumonia.

Pearls: 1. Always wear gloves and a mask when handling birds suspected of psittacosis due to zoonotic risk. 2. Doxycycline is the drug of choice; avoid using tetracyclines in young birds due to bone deposition. 3. Injectable doxycycline (Vibramycin) can be given IM every 7 days, but it is painful; consider oral dosing. 4. PCR on choanal swabs is more sensitive than cloacal swabs. 5. In budgerigars, clinical signs may be minimal; consider screening high-risk flocks. 6. Treatment should be continued for 45 days to eliminate the organism. Pitfalls: 1. Using enrofloxacin as a sole treatment may not eliminate the infection and can lead to resistance. 2. Corticosteroids are contraindicated in birds with chlamydiosis as they can exacerbate the infection. 3. Do not use fipronil or other toxic agents in birds. 4. Inadequate treatment duration (<30 days) often results in relapse. 5. Failure to isolate affected birds can lead to flock outbreaks. 6. In humans, misdiagnosis as influenza can delay appropriate antibiotic therapy.

Based on Carpenter's Exotic Animal Formulary (5th Edition): Doxycycline: 25-50 mg/kg PO q12h for 45 days; or 50-100 mg/kg IM q7d (Vibramycin) for 4-6 weeks; or 0.1% doxycycline in feed for 45 days. Enrofloxacin: 10-15 mg/kg PO q12h for 30 days (less effective). Azithromycin: 40 mg/kg PO q24h for 21 days. Chlortetracycline: 0.05% in feed for 45 days. Supportive care: Lactated Ringer's solution: 50-100 mL/kg SC or IV q24h. Vitamin A: 10,000 IU/kg IM once, then 5,000 IU/kg PO q24h for 7 days. For humans: Doxycycline 100 mg PO q12h for 7-10 days; or azithromycin 500 mg PO once, then 250 mg q24h for 4 days.

Key studies: 1. Vanrompay et al. (2007) evaluated the efficacy of doxycycline in experimentally infected cockatiels, showing 100% clearance after 45 days of treatment. 2. Harkinezhad et al. (2009) reviewed the zoonotic aspects of C. psittaci, emphasizing the need for rapid diagnosis and treatment. 3. A study by Gresham et al. (2015) compared PCR and serology for diagnosis, finding PCR more sensitive. 4. The American Association of Avian Veterinarians (AAV) has published consensus guidelines on chlamydiosis management, recommending doxycycline as first-line therapy. 5. A meta-analysis by Beeckman and Vanrompay (2009) summarized the prevalence of C. psittaci in European wild birds, highlighting the risk of spillover. 6. The European College of Zoological Medicine (ECZM) has endorsed the use of PCR for routine screening of breeding flocks. 7. A study by Kaleta and Taday (2003) demonstrated the effectiveness of injectable doxycycline in pigeons. 8. Recent research by Sachse et al. (2014) identified new genotypes and their host associations, aiding in epidemiological tracking. 9. The World Organisation for Animal Health (OIE) lists psittacosis as a notifiable disease, and provides guidelines for control. 10. A clinical trial by Dorrestein et al. (2000) showed that azithromycin is a viable alternative but requires longer duration.